RA Capital Management 13F holdings, Q1 2014
Holdings as of March 31, 2014 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 29 US equity positions worth $973.5m in its Q1 2014 13F filing. The largest position was SGMOQ at 9.7% of the reported book, followed by ACHILLION PHARMACEUTICALS IN and DICERNA PHARMACEUTICALS INC. Against the Q4 2013 filing, it opened 7 new positions, added to 5 and reduced 6 among the top 29 holdings.
What did RA Capital Management own in Q1 2014? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2013 |
|---|---|---|---|---|---|---|---|
| 1 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 9.7% | $94.4m | 5,222,053 | -0% | held |
| 2 | ACHILLION PHARMACEUTICALS IN | 7.9% | $76.9m | 23,366,007 | 0% | held | |
| 3 | DICERNA PHARMACEUTICALS INC | 7.0% | $68.6m | 2,428,571 | – | new | |
| 4 | DYAX CORP | 6.9% | $66.8m | 7,436,470 | 359% | added | |
| 5 | TXMD THERAPEUTICSMD INC | 6.4% | $62.1m | 9,838,449 | -16% | reduced | |
| 6 | OPHTHOTECH CORP | 6.4% | $62.0m | 1,737,856 | 9% | added | |
| 7 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 6.3% | $61.6m | 1,541,078 | – | new |
| 8 | PROTHENA CORP PLC | 6.1% | $59.6m | 1,554,918 | -5% | reduced | |
| 9 | ARROWHEAD RESH CORP | 5.0% | $48.3m | 2,941,916 | 44% | added | |
| 10 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 4.7% | $46.0m | 4,347,456 | 0% | held |
| 11 | NVAX NOVAVAX INC | Healthcare | 4.6% | $45.0m | 9,938,250 | -8% | reduced |
| 12 | DYNAVAX TECHNOLOGIES CORP | 3.3% | $32.3m | 17,883,954 | 0% | held | |
| 13 | SUNESIS PHARMACEUTICALS INC | 3.3% | $32.2m | 4,869,261 | 0% | held | |
| 14 | XNCR XENCOR INC | Healthcare | 3.3% | $32.0m | 2,725,000 | 0% | held |
| 15 | PTCT PTC THERAPEUTICS INC | Healthcare | 2.6% | $25.7m | 981,761 | 30% | added |
| 16 | REPROS THERAPEUTICS INC | 2.6% | $25.5m | 1,439,048 | – | new | |
| 17 | T8S TESARO INC | 2.1% | $20.6m | 700,000 | 0% | held | |
| 18 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.9% | $18.8m | 1,169,084 | – | new |
| 19 | DERMA SCIENCES INC | 1.7% | $17.0m | 1,339,039 | -33% | reduced | |
| 20 | MIRATI THERAPEUTICS INC | 1.3% | $12.5m | 656,767 | 0% | held | |
| 21 | BLUEBIRD BIO INC | 1.1% | $10.6m | 467,418 | 0% | held | |
| 22 | PSIVIDA CORP | 1.1% | $10.5m | 2,555,659 | 115% | added | |
| 23 | INTERMUNE INC | 1.0% | $10.1m | 300,801 | – | new | |
| 24 | FLEXION THERAPEUTICS INC | 0.8% | $7.4m | 450,000 | – | new | |
| 25 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.6% | $6.1m | 250,000 | -79% | reduced |
| 26 | OCERA THERAPEUTICS INC | 0.6% | $5.6m | 527,797 | -20% | reduced | |
| 27 | MGNX MACROGENICS INC | Healthcare | 0.6% | $5.5m | 199,398 | 0% | held |
| 28 | ALIMERA SCIENCES INC | 0.5% | $5.3m | 666,667 | – | new | |
| 29 | MEI PHARMA INC | 0.5% | $4.5m | 408,333 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.